| pubmed-article:8018963 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8018963 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8018963 | lifeskim:mentions | umls-concept:C0034802 | lld:lifeskim |
| pubmed-article:8018963 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:8018963 | lifeskim:mentions | umls-concept:C1514475 | lld:lifeskim |
| pubmed-article:8018963 | lifeskim:mentions | umls-concept:C1552617 | lld:lifeskim |
| pubmed-article:8018963 | lifeskim:mentions | umls-concept:C0282443 | lld:lifeskim |
| pubmed-article:8018963 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:8018963 | pubmed:dateCreated | 1994-7-29 | lld:pubmed |
| pubmed-article:8018963 | pubmed:abstractText | Epidermal growth factor receptor (EGFR) and estrogen receptor (ER) were assayed by ligand binding in tumors from 370 patients with primary breast carcinoma with a median follow up of 18 months. Forty seven percent (175/370) and 57% (210/370) of tumors had > 20 fmol/mg and > 10 fmol/mg of EGFR and ER respectively. There was a highly significant inverse relationship between EGFR and ER (p = 0.0032). There was also a significant association between EGFR and patient age (p = 0.0006) but not correlation between EGFR and lymph node status, tumor grade, or tumor size (p = 0.104, p = 0.198, and p = 0.085 respectively). In a univariate analysis of all patients, EGFR expression was not associated with a significant reduction in overall survival (OS). However, there was a significant decrease in relapse-free survival (RFS) and OS in node negative EGFR positive patients (p = 0.03 and p = 0.05 respectively). In a multivariate analysis (Cox proportional hazard model) of all patients, lymph node status was an independent prognostic indicator for OS and RFS (p < 0.00005) and p = 0.00005 respectively), ER status for RFS (p = 0.0006), and EGFR (in the node negative model) for RFS (p = 0.03). When all patients were stratified for EGFR and ER, there was a significant difference in RFS and OS such that EGFR positive and ER negative had the worst prognosis (p = 0.0034 and p = 0.005 respectively). | lld:pubmed |
| pubmed-article:8018963 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8018963 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8018963 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8018963 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8018963 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8018963 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8018963 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8018963 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:8018963 | pubmed:issn | 0167-6806 | lld:pubmed |
| pubmed-article:8018963 | pubmed:author | pubmed-author:HarrisA LAL | lld:pubmed |
| pubmed-article:8018963 | pubmed:author | pubmed-author:SmithKK | lld:pubmed |
| pubmed-article:8018963 | pubmed:author | pubmed-author:GreenallMM | lld:pubmed |
| pubmed-article:8018963 | pubmed:author | pubmed-author:LEEF PFP | lld:pubmed |
| pubmed-article:8018963 | pubmed:author | pubmed-author:HollyerJJ | lld:pubmed |
| pubmed-article:8018963 | pubmed:author | pubmed-author:HastrichDD | lld:pubmed |
| pubmed-article:8018963 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8018963 | pubmed:volume | 29 | lld:pubmed |
| pubmed-article:8018963 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8018963 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8018963 | pubmed:pagination | 41-9 | lld:pubmed |
| pubmed-article:8018963 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:8018963 | pubmed:meshHeading | pubmed-meshheading:8018963-... | lld:pubmed |
| pubmed-article:8018963 | pubmed:meshHeading | pubmed-meshheading:8018963-... | lld:pubmed |
| pubmed-article:8018963 | pubmed:meshHeading | pubmed-meshheading:8018963-... | lld:pubmed |
| pubmed-article:8018963 | pubmed:meshHeading | pubmed-meshheading:8018963-... | lld:pubmed |
| pubmed-article:8018963 | pubmed:meshHeading | pubmed-meshheading:8018963-... | lld:pubmed |
| pubmed-article:8018963 | pubmed:meshHeading | pubmed-meshheading:8018963-... | lld:pubmed |
| pubmed-article:8018963 | pubmed:meshHeading | pubmed-meshheading:8018963-... | lld:pubmed |
| pubmed-article:8018963 | pubmed:meshHeading | pubmed-meshheading:8018963-... | lld:pubmed |
| pubmed-article:8018963 | pubmed:meshHeading | pubmed-meshheading:8018963-... | lld:pubmed |
| pubmed-article:8018963 | pubmed:meshHeading | pubmed-meshheading:8018963-... | lld:pubmed |
| pubmed-article:8018963 | pubmed:meshHeading | pubmed-meshheading:8018963-... | lld:pubmed |
| pubmed-article:8018963 | pubmed:meshHeading | pubmed-meshheading:8018963-... | lld:pubmed |
| pubmed-article:8018963 | pubmed:meshHeading | pubmed-meshheading:8018963-... | lld:pubmed |
| pubmed-article:8018963 | pubmed:meshHeading | pubmed-meshheading:8018963-... | lld:pubmed |
| pubmed-article:8018963 | pubmed:meshHeading | pubmed-meshheading:8018963-... | lld:pubmed |
| pubmed-article:8018963 | pubmed:meshHeading | pubmed-meshheading:8018963-... | lld:pubmed |
| pubmed-article:8018963 | pubmed:meshHeading | pubmed-meshheading:8018963-... | lld:pubmed |
| pubmed-article:8018963 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8018963 | pubmed:articleTitle | The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. | lld:pubmed |
| pubmed-article:8018963 | pubmed:affiliation | Nuffield Department of Pathology, John Radcliffe Hospital, Oxford, UK. | lld:pubmed |
| pubmed-article:8018963 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8018963 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8018963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8018963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8018963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8018963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8018963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8018963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8018963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8018963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8018963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8018963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8018963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8018963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8018963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8018963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8018963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8018963 | lld:pubmed |
